DNLI 250117 30.00P (DNLI250117P30000) Stock Options, News & Quotes

US OptionsDetailed Quotes

DNLI250117P30000

Watchlist

8.20
+2.60+46.43%

15min DelayClose Jan 17 16:00 ET

8.20High8.20Low

Intraday

5D
Daily

News

Why Denali Therapeutics (DNLI) Is the Biotech Stock With Biggest Upside Potential
Yahoo Finance11:18 ET
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32
Moomoo NewsJan 15 21:31 ET · Ratings
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
TipRanksJan 15 20:35 ET · Ratings
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
BenzingaJan 15 14:26 ET
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
Moomoo NewsJan 14 08:34 ET · Ratings
Denali Therapeutics (DNLI) Receives a Buy From TD Cowen
TipRanksJan 14 07:57 ET · Ratings

Comments

Meltyy

May 16, 2024 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Kevin Travers

Feb 27, 2024 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

Moomoo AI

Feb 7, 2024 06:59

Denali Therapeutics' continuous stock price drop questions the initial investment decision. The company's struggle to increase revenue while unprofitable worries investors. Despite a recent 3.9% rise, the company's disappointing performance over the past years resulted in a yearly 3% total loss for shareholders over five years.

Denali Therapeutics (NASDAQ:DNLI) Shareholders Are up 3.9% This Past Week, but Still in the Red Over the Last Three Years

MangoXoXo

Jan 30, 2024 18:16

$Denali Therapeutics (DNLI.US)$ 👀

Meltyy

Jan 24, 2024 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...